US panel urges approval of J&J psoriasis drug

SILVER SPRING, Md., June 17 (Reuters) - A U.S. advisory panel unanimously recommended approval of Johnson & Johnson's (JNJ.N: Quote, Profile, Research, Stock Buzz) experimental drug ustekinumab to treat adults with moderate to severe cases of psoriasis.

The Food and Drug Administration will consider the advice before making a final decision, which is expected by September. The FDA usually follows panel recommendations.